Quantcast

Latest Bioniche Life Sciences Inc. Stories

2014-08-19 08:30:02

BELLEVILLE, ON, Aug. 19, 2014 /PRNewswire/ - Bioniche Life Sciences Inc. (TSX: BNC) today announced that it is targeting Q1/2015 for the filing of a Biologics License Application (BLA) with the United States Food and Drug Administration (FDA) for Bioniche's lead program Mycobacterial Cell Wall-Nucleic Acid Complex (MCNA) for the treatment of patients with high grade non-muscle invasive bladder cancer that have failed Bacillus Calmette-Guérin (BCG) therapy. This projected timeline...

2014-07-29 08:32:30

BELLEVILLE, ON, July 29, 2014 /PRNewswire/ - Bioniche Life Sciences Inc. (TSX: BNC) today announced the submission to the US Food and Drug Administration (FDA) Office of Orphan Products Development, an application for Orphan Drug Designation for its Mycobacterial Cell Wall-Nucleic Acid Complex (MCNA) sterile suspension for the treatment of patients with Bacillus Calmette-Guérin (BCG) refractory/relapsing high grade non-muscle invasive bladder cancer. The decision to proceed...

2014-07-18 08:24:51

BELLEVILLE, ON, July 18, 2014 /PRNewswire/ - Bioniche Life Sciences Inc. (TSX: BNC) today provided a key regulatory update on its flagship Phase 3 program, Mycobacterial Cell Wall-Nucleic Acid Complex (MCNA) sterile suspension for the treatment of patients with Bacillus Calmette-Guérin (BCG) refractory high grade non-muscle invasive bladder cancer. MCNA U.S. Regulatory Update Following several months of active dialogue with the U.S. Food and Drug Administration (FDA),...

2014-06-13 08:24:29

BELLEVILLE, ON, June 13, 2014 /PRNewswire/ - Bioniche Life Sciences Inc. (TSX: BNC) - ("Bioniche" or the "Company"), a clinical stage biotechnology company whose anchor product is a Phase III treatment for non-muscle-invasive bladder cancer, today announced that Dr. Michael Berendt, Chief Executive Officer and Chief Scientist of Bioniche Life Sciences Inc., will present a corporate update at the Bloom Burton & Co. Healthcare Investor Conference at the Toronto Board of Trade on...

2014-06-03 08:33:08

BELLEVILLE, ON, June 3, 2014 /PRNewswire/ - Bioniche Life Sciences Inc. (TSX: BNC) today provided corporate updates on a number of key strategic initiatives including: -- Continued execution of Cost Reduction/Strategic Expenditures Review -- Completion of Asset Disposition Program -- Vaccine Manufacturing (VMC) Sales Process -- Urocidin(TM) Regulatory Update Strategic Expenditures Review Initiated in December 2013, management...

2014-05-14 16:29:21

(all figures are in Canadian dollars unless otherwise noted) BELLEVILLE, ON, May 14, 2014 /PRNewswire/ - Bioniche Life Sciences Inc. (TSX: BNC), a clinical stage biotechnology company, today announced financial results for the third quarter of Fiscal 2014 (ended March 31, 2014). Highlights of the year-to-date include: -- Successful execution of Animal Health division sale to Vétoquinol for $61 million plus working capital adjustment; --...

2014-04-15 20:23:13

LURE, FRANCE and BELLEVILLE, ON, April 15, 2014 /PRNewswire/ - Vétoquinol (NYSE Euronext Paris: VETO) and Bioniche Life Sciences Inc. (TSX: BNC), today jointly announced the closing of the sale of Bioniche's Animal Health business to Vétoquinol. The two companies announced the signing of a share purchase agreement in February that was subject to the approval of Bioniche shareholders. At a Special Meeting of Shareholders held yesterday, 97.4% of the Shares that were voted were in...

2014-04-14 12:36:38

BELLEVILLE, ON, April 14, 2014 /PRNewswire/ - Bioniche Life Sciences Inc. (TSX: BNC) today announced that its shareholders have voted in favour of the sale of the Company's Animal Health business to Vétoquinol SA. At a Special Meeting of Shareholders held this morning in Toronto, 39.4% of the issued and outstanding shares were voted, with 97.4% of those voting in favour of the sale transaction. The transaction is expected to close tomorrow. About Bioniche Life Sciences...

2014-04-03 16:24:27

BELLEVILLE, ON, April 3, 2014 /PRNewswire/ - Bioniche Life Sciences Inc. (TSX: BNC) today announced that it has successfully monetized two non-core properties for net proceeds in excess of $1 million. Over the past several months, the Board of Directors and management team have developed and have been implementing a strategic expenditures review which included identifying and divesting non-core assets. The sale of the property adjacent to the Company's Belleville, Ontario...

2014-04-03 12:29:32

BELLEVILLE, ON, April 3, 2014 /PRNewswire/ - Bioniche Life Sciences Inc. (TSX: BNC) today announced that Institutional Shareholder Services (ISS) has recommended that shareholders vote FOR the special resolution pertaining to the sale of all of the Corporation's Animal Health business to Vétoquinol SA, to be considered at the upcoming Special Meeting of Shareholders: Monday, April 14, 2014 9:00 .m. EST Norton Rose Fulbright Canada Board Rooms D, E, and F Royal Bank Plaza, South...


Word of the Day
mallemaroking
  • Nautical, the visiting and carousing of sailors in the Greenland ships.
This word is apparently from a confusion of two similar Dutch words: 'mallemerok,' a foolish woman, and 'mallemok,' a name for some persons among the crew of a whaling vessel.